An experimental cancer medication called ISM6331 has shown preliminary evidence of tumor shrinkage in a small group of patients with mesothelioma, according to an abstract presented at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid.
The findings are encouraging but early. ISM6331 is not an approved treatment, and researchers have not established whether it improves survival or offers advantages over existing therapies. The findings below reflect the abstract's April 9, 2026 data cutoff, not necessarily any later updates presented orally on October 25.
What did the researchers find?
The official ESMO abstract reports 20 patients enrolled by April 9, 2026. Twelve had mesothelioma; eight had other advanced solid tumors.
Among seven mesothelioma patients whose tumor responses could be evaluated, two experienced confirmed partial responses, with reductions of 75% and 42% in measured tumor burden. The abstract reports an objective response rate of 28.5% (2 of 7) and disease control in four of seven evaluable mesothelioma patients (57.1%). The two responding patients had previously received four or five lines of treatment.
These observations suggest possible antitumor activity in some heavily pretreated patients. But the number of evaluable patients is very small, and this early study did not include a randomized comparison group. Tumor shrinkage does not necessarily establish longer survival or improved quality of life.
How does ISM6331 work?
ISM6331 is an oral investigational medication designed to inhibit proteins called TEAD1–4. These proteins participate in signaling associated with the Hippo pathway, a biological system involved in regulating cell growth and survival. Researchers are studying whether inhibiting TEAD activity can interfere with tumor growth.
ISM6331 was developed with assistance from artificial intelligence-based drug-design technology. That describes the drug-development process; it does not establish that the medication is safe or effective in patients.
What do we know about safety?
At the April 9 cutoff, the abstract reported no dose-limiting toxicities and no treatment-related dose interruptions, reductions, or discontinuations among the 20 participants. Grade 1 proteinuria—protein detected in the urine—was reported in 15% of participants.
These are preliminary observations, not a complete safety assessment. Larger studies and longer follow-up are needed to evaluate uncommon, delayed, or serious adverse effects.
Is ISM6331 available to patients?
ISM6331 remains investigational and is not FDA-approved for treating mesothelioma. The clinical trial is registered as NCT06566079. Patients interested in learning whether they might qualify should review the official registration and discuss the study with their treating oncologist or a mesothelioma specialist. Eligibility and enrollment status can change.
FDA orphan-drug or Fast Track designations, where applicable, do not constitute approval or proof of effectiveness.
What should patients ask their doctors?
- Are any clinical trials appropriate for my diagnosis and treatment history?
- Could molecular testing help identify relevant investigational treatments?
- What are the known risks and uncertainties of an early-stage trial?
- How might trial participation affect my other treatment options?
Clinical-trial participation does not guarantee benefit. Patients should not change prescribed treatment based on preliminary conference findings.
Why this research matters
Mesothelioma remains a serious cancer, and additional treatment options are needed, particularly when disease progresses after established therapies. These ISM6331 findings provide an early signal that targeting Hippo–TEAD signaling warrants further investigation—not evidence of a cure or new standard of care.
For broader background, see our mesothelioma treatment resource, mesothelioma information center, and Mesothelioma News Desk.
Original research and additional information
- ESMO Congress 2026 official presentation calendar — search for ISM6331 to open presentation 1004RO and its abstract, presented by Melina E. Marmarelis on October 25, 2026; data cutoff April 9, 2026.
- ClinicalTrials.gov — NCT06566079 — study registration and eligibility information.
- Insilico Medicine, October 21, 2026 — developer's conference announcement.
- National Cancer Institute — Mesothelioma Treatment — established treatment context.
Source and funding note: The original ESMO abstract identifies Insilico Medicine Hong Kong Limited as the study's responsible legal entity and funder and contains investigator conflict-of-interest disclosures. Our summary is based on the published abstract, not independently verified updated oral-presentation results.
Medical information notice: Humpleby & Strauss, P.C. is a law firm, not a medical provider. This article is for general education and is not medical advice. Treatment decisions should be made with qualified medical professionals. See our editorial standards.